Inflammatory conditions like rheumatoid arthritis, inflammatory bowel disease and psoriasis can reduce your patients’ quality of life and limit their lifestyle choices. Using a biologic anti-TNF treatment can help your patients to...

rewrite their story

Hulio® (adalimumab) is used to treat a number of autoimmune inflammatory disorders when other treatments have failed.

About Hulio®

Hulio® is an approved biosimilar of adalimumab. It is a recombinant human monoclonal antibody (mAB). Adalimumab is the third tumour necrosis factor alpha (TNFα)-blocking agent available in the form of a biosimilar, following infliximab (another monoclonal antibody, mAb) and etanercept (a fusion protein).1

Learn more

How to use
Hulio®

Hulio® is available in 3 presentations including a pre-filled pen for patient convenience.

Learn more

How Hulio®
works

Hulio® is a recombinant human monoclonal antibody that helps to reduce the symptoms of immune-mediated diseases in children and adult population, such as moderate-to-severe active rheumatoid arthritis (RA), moderate-to-severe chronic plaque psoriasis (Pso) and inflammatory bowel disease (IBD: Crohn’s disease and ulcerative colitis).

Learn more

Dosing

Hulio® has been approved for the treatment of immune-mediated conditions among children and adults. The dosage of Hulio in adults depends on the immune-mediated condition they are being treated for. In children, dosage depends on their body weight too. Please refer to the Hulio® SmPC for full prescribing information

Learn more

Restricted access

The website you are trying to access is designed for healthcare professionals only - the content is not designed for the general public.

Are you a healthcare professional based in UK or Ireland?

YES
NO

Report side effects

▼This medicine is subject to additional monitoring. This will allow quick identification of new safety information. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare providers are asked to report any suspected adverse reactions. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. In order to support effective tracking and traceability of biologics including biosimilars, it is recommended that the brand name and batch number are recorded and used when reporting adverse events.

You are now leaving the Hulio® uk website